Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen Completed Phase 2 Trials for Meningococcal Infections / Neisseria Meningitidis / Meningitis Prevention

CompletedPrevention2 IdentifierTitleDrugs
NCT00700635Dose Comparison Study of Menactra® in US Children
NCT00258856Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®
NCT00269477Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®
NCT00643916Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age
NCT01442675Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine
NCT01165242Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults
NCT00454909Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.